Kornimate/medical-research-clean huggingface dataset:
cd73+ th1.17 in rheumatoid arthritis and psoriatic arthritis

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis

Summary: prospective study to investigate the correlation between cd39/cd73 expression by the different t lymphocyte subpopulations in the blood and synovial fluid (if available) into patients with chronic inflammatory rheumatism ra and psa types, with the rheumatic activity, the background therapy (with methotrexate (mtx)) and the response to this treatment.

th1.17 compose a recently described subset of highly polyfunctional and thus potentially more harmful cd4+ effector t cells (teff) than classical th17 as they co-produce interferon-γ (ifn-γ) and interleukin-17a (il-17a). for this reason, th1.17 rise increasing interest in ra and psa since they seem involved in their pathophysiology. hyper activation of teff in ra and psa results partly from a deficiency in regulatory mechanisms of teff's pro-inflammatory functions. the ecto-nucleotidase cd73 delineates teff enriched in th1.17 features and acts as a regulatory mechanism for these pro-inflammatory cells. considering that mtx, usually used as first line treatment of ra and psa, increases extracellular concentrations of adenosine monophasphate (amp) and immunosuppressive adenosine, the investigators hypothesized that cd4+cd73+ t cell effector population enriched in th1.17 and th17 cells may participate in the pathogenicity of ra and psa but also in the resistance to mtx treatment through the specific expression of cd73 essential for ado generation and which is down-regulated on proliferating t cells.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * patients naive to biologics * patients with ra fulfilling the american college of rheumatology and european league against rheumatism 2009 criteria * patients with psa fulfilling the classification for psa (caspar) criteria exclusion criteria: * none
the efficacy of balance gaming as an adjunct to vestibular rehabilitation therapy

Conditions: Vestibular Diseases; Disturbance; Balance, Labyrinth

Summary: patients with a unilateral vestibular loss often complain of dizziness and imbalance. movement usually increases these symptoms often resulting in patients avoiding these movements, causing further limitations in their activities of daily living. vestibular rehabilitation (vr) involves a series of adaptation and balance exercises to improve symptoms of postural stability. there is evidence that stroke patients gain benefit in their rehabilitation from using gaming consoles (nintendo wii balance) and we believe that similar advantages can be shown for balance patients. we plan a 3 arm study. as there is a considerable wait list for vr, the first arm will receive a wii console and instructions to use it on the wait list and during vr. the second arm will receive a wii console and instructions at the end of the waiting list and will use it during vr only and the control group will receive no wii. all will spend the same time on the wait list and will receive identical assessments and vr

none required

Eligibility criteria:
inclusion criteria: * unilateral vestibular loss * uncompensated * present for \>6 months exclusion criteria: * age \<18 years

Keywords: balance rehabilitation vestibular
exploring p-wave duration in arrhythmia recurrence in patients undergoing af ablation

Conditions: Atrial Fibrillation Recurrent

Summary: the aim of this study is to investigate whether p-wave duration in a baseline surface 12-lead ecgs correlates with recurrence of af recurrence post successful ablation at the time of the procedure.

patients with paroxysmal af are often treated arrhythmia-free (75%) with a single catheter ablation at 12 months post procedure . in contrast, in patients with persistent af or long persistent af, catheter ablation is more complex and often yields in lower success rates of around 50% often requiring multiple attempts . the success rates remain low despite several different ablation sites having been proposed (additional lines plus pvi, epicardial approach). there is growing evidence that pwd is associated with the extent of left atrial scarring and this can be used a potential predictor of af recurrence . moreover, results from the investigators group has previously shown that pwd correlated with the duration of the af and this could be altered by extensive ablation . it is uncertain whether pwd prior to any procedure for persistent af, long persistent or paroxysmal af can accurately predict failure of procedure. this is a single centre observational study of persistent, long persistent and paroxysmal af population who have undergo af cryoablation in university hospital plymouth . all patients receive this current procedure as standard of care. this study does not involve any patient contact out of the standard routine clinical follow up and therefore no public involvement has been sought.

Eligibility criteria:
inclusion criteria: 1. patients with persistent, long persistent or paroxysmal af undergone af cryoablation from 2016 onwards 2. age \>18 3. patient does not meet exclusion criteria - exclusion criteria: 1. patients whose records cannot be obtained 2. patients with persistent, long persistent or paroxysmal af undergone af ablation prior to 2016 3. patients with no documented ecg in sinus rhythm prior to ablation 4. patients not undergoing cryoablation for af -

Keywords: p-wave duration af cryoablation
prevalence of antibodies and cytokines in participants with chronic granulomatous disease

Conditions: Chronic Granulomatous Disease (CGD)

Summary: this research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with cgd.

in this observational study, blood samples will be collected from adult and pediatric patients with cgd. the level of circulating adenovirus antibodies and inflammatory cytokines will be measured to characterize the prevalence of these markers in this population.

Eligibility criteria:
inclusion criteria: * the participant must have been diagnosed with cgd based on the referring physician's confirmation that nadph oxidase activity is ≤5% (i.e., the percentage of dihydrorhodamine-positive \[dhr+\] cells is ≤5% by flow cytometry) or based on confirmed pathogenic mutation in a cgd associated gene (cybb, cyba, ncf1, ncf2, ncf4, or cybc1). * the participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent. * the participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (icf). exclusion criteria: * the participant has undergone an allogeneic bone marrow transplant or investigational gene therapy. * the participant is unable to comply with the sample collection procedure based on investigator judgment.

Keywords: cgd x-cgd chronic granulomatous disease granulomatous disease, chronic autosomal recessive chronic granulomatous disease
pilot study of nutrition in maintenance hemodialysis patients

Conditions: End-Stage Renal Disease; Meals; Hemodialysis

Summary: this pilot study aims to produce preliminary data on the safety of providing high-protein meals to patients during dialysis, and effects of this intervention on nutritional status and quality of life outcomes. this is a non-randomized, parallel arm study. meals provided will follow recommended dietary guidelines for hd patients and will provide approximately 1/3 of daily recommended protein intake. patients will be allocated to either the treatment or control group by hd shift schedule. 2 months of baseline data will be collected, followed by 9 weeks of meal intervention/control and data collection. the primary outcome will be frequency of hypotensive events during dialysis requiring intervention. secondary outcomes will include highest and lowest systolic blood pressure during dialysis, blood biochemistries including measures of renal function, nutritional status, and electrolyte balance; dialysis compliance; fluid retention; sleep and other quality of life measures; and dietary intake data.


Eligibility criteria:
inclusion criteria: * men and women * any race * age 18 years or older * maintenance hemodialysis patients exclusion criteria: • patients with dysphagia that cannot be accommodated by texture modifications, or those exclusively npo/requiring tube feeding or parenteral feeding
safety and efficacy of a switch to doravirine/islatravir in participants with hiv-1 (mk-8591a-017)

Conditions: HIV Infection

Summary: this study will evaluate the safety and efficacy of a switch to mk-8591a (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (hiv-1)-infected participants virologically suppressed on a protocol-specified background antiretroviral regimen. the primary hypothesis is that a switch to mk-8591a will be non-inferior to continued treatment with baseline antiretroviral therapy (art) as assessed by the percentage of participants with hiv-1 ribonucleic acid (rna) ≥50 copies/ml at week 48.


Eligibility criteria:
inclusion criteria: * is hiv-1 positive * has been receiving continuous, stable oral 2-drug or 3-drug combination (± pharmacokinetic (pk) booster) with documented viral suppression (hiv-1 rna \<50 copies/ml) for ≥3 months prior to signing informed consent and has no history of prior virologic treatment failure on any past or current regimen. * female is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (wocbp); is a wocbp and using an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle; a wocbp must have a negative highly sensitive pregnancy test (\[urine or serum\] as required by local regulations) within 24 hours before the first dose of study intervention; if a urine test cannot be confirmed as negative (e.g. an ambiguous result), a serum pregnancy test is required. in such cases, the participant must be excluded from participation if the serum pregnancy result is positive exclusion criteria: * has hiv-2 infection * has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator * has an active diagnosis of hepatitis due to any cause, including active hepatitis b virus (hbv) co-infection * has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous kaposi's sarcoma * is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies * is currently taking long-acting cabotegravir-rilpivirine * is currently participating in or has participated in a clinical study with an investigational compound or device from 45 days prior to day 1 through the study treatment period * has a documented or known virologic resistance to dor * female expects to conceive or donate eggs at any time during the study
cardiovascular disease and the effects of a cross-curricular physical activity intervention

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to investigate the effects of a cross-curricular physical activity intervention on cardiovascular disease risk factors in 11-14 year olds. the null hypothesis states that the intervention will have no effect on cardiovascular disease risk factors.

cardiovascular disease is the leading cause of mortality worldwide. risk factors associated with cardiovascular disease including obesity, blood pressure and blood lipids have been shown to track from childhood through to adulthood. the prevalence of overweight and obesity for children (4-18 years) in the uk is reported to be 15 % and 4 % respectively. furthermore, in comparison to england (2.9 %) obesity is more prevalent for those living in scotland (7.6 %) and wales (6.5 %). previous research from two welsh secondary schools indicate overweight and obesity rates for boys and girls aged 12-13 to be even greater at 26 % and 38 % respectively. further to this, 19 % were identified as having elevated total cholesterol (≥5.2 mmol/l). for many, overweight and obesity is the result of the combined effect of excess energy consumption and inadequate physical activity. previous school-based physical activity interventions have demonstrated modest improvements to cardiovascular disease risk factors by implementing extra-curricular activities or improving current physical education curriculum. few have attempted to increase physical activity using normally, class-room taught curriculum subjects. this study examines the impact of activity knowledge circuits to combat cardiovascular disease risk factors in 11-14 year old children.

Eligibility criteria:
inclusion criteria: * any pupil attending years 7, 8, and 9 of a secondary comprehensive school in south wales exclusion criteria: * any pupil with an injury or illness that prevented them from taking part in any form of physical activity.
effectiveness of wound closure using v-loc™ 90 sutures in lipoabdominoplasty patients

Conditions: Open Surgical Wounds

Summary: vlock suture studied in abdominal wound closure. time and cosmesis was studied


Eligibility criteria:
inclusion criteria: * lipoabdominoplasty patients exclusion criteria: * poor health, * history of radiation, * smoking

Keywords: abdominoplasty
switching from zidovudine to an nnrti or lopinavir/ritonavir in patients treated with zidovudine/ lamivudine/abacavir.

Conditions: HIV Associated Lipodystrophy Syndrome.; HIV; Hypercholesterolemia; Lipoatrophy

Summary: highly active antiretroviral therapy (haart) has improved the long time survival of hiv infected individuals. however an increasing number of hiv-patients have developed metabolic and morphological alterations including peripheral lipoatrophy. the main hypothesis of the study is that switching from thymidine-analogue based haart will reverse lipoatrophy. we plan to perform an observational study recruiting up to 100 hiv-infected patients receiving trizivir (zidovudine/lamivudine/abacavir). the patients will be offered an nrti or lopinavir/ritonavir instead of zidovudine or they can choose to continue with trizivir. the main endpoint is changes in peripheral fat mass as determined by dexa-scanning.


Eligibility criteria:
inclusion criteria: * currently treated with lamivudine, zidovudine and abacavir * viral load \< 200 copies/ml * ability to understand and provide written informed consent. exclusion criteria: * women being pregnant or breast-feeding. * fertile women using no safe contraception. * patients with active intravenous drug use. * abuse of alcohol, which in the opinion of the treating physician will reduce the patient´s ability to follow a therapeutic regimen and evaluations of the protocol. * creatinine \> 200 mmol/l. * alt or ast \> 5 times upper normal value (200u/l).
tap block efficacy after lumbar spine surgery through anterior approach: a randomized, placebo-controlled study

Conditions: Pain, Postoperative

Summary: anterior lumbar interbody fusion (alif) as well as direct lateral interbody fusion (dlif) are established techniques for lumbar interbody fusion. in contrast with posterior approaches, they allow free approach to the anterior disc space without opening of the spinal canal or the neural foramina. however, the additional anterior approach conveys specific concerns, including abdominal pain that may delay recovery after surgery. the transversus abdominis plane (tap) block is a validated approach for postoperative pain relief following abdominal surgeries. there is currently no evidence of the possible benefits of tap block as part of multimodal pain management after alif/dlif surgery. the investigator hypothesize that a single-injection tap block reduces opioid consumption after anterior lumbar fusion surgery. the main goal of this prospective, randomized, double-blind, placebo-controlled study is to demonstrate a \>35% reduction in opioid consumption during the 24h following alif/dlif surgery.

clinical trial : therapeutic, prospective, randomized,double blind, placebo-controlled, with parallel group, of superiority, in intention to treat, monocentric study. the main steps of the study are: * preoperative assessment of eligibility * exclusion and inclusion criteria, written informed consent, baseline preoperative assessment (see specific section) * randomization (using a computer generated list) immediately before induction of anesthesia * tap block: ropivacaine + clonidine (experimental group, n=20) or saline (control group; n=20) * anesthesia (propofol, sufentanil, cisatracurium, ketamine and desflurane) and postoperative analgesia (paracetamol, ketoprofen, nefopam, and patient-controlled analgesia with morphine) similar in both groups * surgical procedure * primary outcome parameter (morphine consumption first 24 hours; see specific section) * secondary endpoints (see specific section, up to 6 months following surgery)

Eligibility criteria:
inclusion criteria: * man or woman over the age of 18 yr * patients with insurance coverage * patients able to provide free and informed consent * patients undergoing surgery by the alif or dlif approaches exclusion criteria: * patients receiving opioids as chronic treatment * patients with contra-indication to regional anesthesia or tap block * patients unable to consent * patient refusal * patients with contra-indication to any drug included in the anesthesia or analgesia protocol * pregnancy or breast-feeding women
analysis of p-selectin expression on platelets of blood from lung cancer patients

Conditions: Lung Cancer

Summary: purpose: selectins are vascular cell adhesion molecules involved in adhesive interactions of leukocytes and platelets and endothelium within the blood circulation. plasma soluble p selectin (sp-selectin), is a one of member of selectin family, an adhesion molecule and component of the membrane of the platelet alpha granulate has been proposed as a one marker of platelet activation. in this study we evaluate of expression of p selectin on platelets of blood between serum samples from lung cancer and healthy individuals.

material and methods: the investigators enrolled patients with lung cancer which divided on 3 group: 1- 23 patients with operating tumor; 2-ten patients with advanced and metastatic disease who received palliative rt (rt - radiotherapy); 3-five patients with advanced inoperable disease, who received radical rt or rt + ct (ct- chemotherapy). in 1 group the specimens of blood we collected before surgery and 1-2 month after. in 2 group - before palliative treatment and in group 3 before radical treatment and one month after completion treatment. to compare to serum specimens from patients with lung cancer was obtained plasma from healthy volunteers. serum separation and raman spectroscopy analysis: a single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. the raman spectra (rs) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min. the raman system (renishaw invia microscope integrated with leica microscope) was calibrated with a silicon standard using the raman peak at 520 cm-1. multiple scans were conducted on the solid residue by moving the substrate on an x - y stage. the wavelength of excitation was 785 nm and the laser beam was focused on the surface of the sample with a 50x objective. the radius on the beam was 3.0 µm and the laser power irradiation over the sample was 5mw. each spectrum was taken with an exposure of 30s, 10 accumulation and collected in the region from 400 to 1540 cm-1.

Eligibility criteria:
inclusion criteria: * confirmed lung cancer * who 0-2 * 6 month after chemotherapy in palliative patients exclusion criteria: * double cancer * another cancer * chemotherapy in radical patients * prior external beam radiation in an interview with the patient

Keywords: p-selectin lung cancer raman spectroscopy
platelet function during ecmo (extra corporeal membrane oxygenation)

Conditions: Platelet Function; Thrombocytopenia

Summary: platelet transfusions are routinely administered during neonatal ecmo, with an average of 1.3 platelet transfusions per day being administered while a patient is undergoing ecmo treatment. the cause of thrombocytopenia during ecmo largely involves platelet adherence to the oxygenator membrane. platelet transfusions carry risks such as infections with bacteria or yeast, and development or worsening of pulmonary hypertension. it is likely that if fewer platelet transfusions can be administered during the ecmo run, the cumulative adverse effects of platelet transfusions would diminish and patient outcomes improve. in order to better understand platelet function during ecmo, the investigators plan to serially determine the circulating platelet mass, plasma platelet factor 4 concentration, megakaryocyte mass (estimated by plasma thrombopoietin concentration), and platelet function as quantified by pfa100. any patient on ecmo will be eligible for this pilot study of 5 patients. by understanding changes in platelet function, we hope to design a future study that may modify the frequency or need for platelet transfusions during ecmo.

platelet transfusions are routinely administered during neonatal ecmo, with an average of 1.3 platelet transfusions per day being administered while a patient is undergoing ecmo treatment.1 in general, a platelet transfusion is ordered for a patient on ecmo if the platelet count falls below 100,000/ul in order to prevent generalized hemorrhaging.1,2 the cause of thrombocytopenia during ecmo largely involves platelet adherence to the oxygenator membrane,3 but other mechanisms are also likely to be involved.4 platelet transfusions carry risks as well as benefits.5 infections with bacteria or yeast are the most commonly reported complications of platelet transfusions,6,7 but with multiple platelet transfusions the development or worsening of pulmonary hypertension may be another common adverse effect.8,9 pulmonary hypertension can be the result of administering biologically active pro-inflammatory proteins (known to be present in platelet transfusions) into the venous circulation. of note, the first capillary bed encountered will be within the pulmonary circulation. it is likely that if fewer platelet transfusions could safely be administered during the ecmo run, the cumulative adverse effects of platelet transfusions would diminish and thereby patient outcomes might improve.

Eligibility criteria:
inclusion criteria: * any patient on ecmo will be eligible for study.

Keywords: to better understand platelet function during ecmo
clinical study of lyophilized plasma in patients with liver disease

Conditions: Liver Disease

Summary: a multi-center, phase 2, randomized, controlled study of the effect of lyophilized plasma in patients with liver disease.


Eligibility criteria:
inclusion criteria: 1. male or female patients at least 18 years of age. 2. patients with liver disease. 3. patients who have need for plasma therapy for a surgical or an invasive procedure or who have evidence of bleeding. 4. patients with an elevated international normalized ratio due to liver disease. 5. patients who have given written informed consent or for whom written informed consent has been obtained from the patient's legal representative on their behalf. 6. patients able and willing to comply with the procedures laid out in the study protocol. exclusion criteria: 1. patients who are clinically unstable. 2. patients who have received mediations that could interfere with results of laboratory testing. 3. patients who have congenital or acquired coagulopathies of non-hepatic origin. 4. pregnant or nursing women. 5. active illicit drug use. 6. patients participating in another clinical treatment study currently or during the past 1 month prior to study inclusion. 7. patients previously enrolled in this study.